Abstract 1854P
Background
Impaired perception of time has been associated with many psychiatric and neurological diseases. Time perception has been studied with different validated scales in the literature. However, the length of these scales limits its feasibility. The aim of our study was to evaluate the relationship of “1 minute” time perception with depression and anxiety in cancer patients receiving chemotherapy.
Methods
The cancer patients receiving active systemic therapy were included in the study. Time perception assessment was performed by testing how they perceived the 1-minute period. The patients were asked to guess the length of 1 minute by using a chronometer. Time perception duration (TPD) were recorded. The median 39 seconds was used to categorize patients as fast and slow time perception. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale (HADS).
Results
In the study; 242 patients with a median age of 61 (33-88 years) were evaluated. In the TPD evaluation, the median estimation time was 39s (7-135sec) and 50.4% was found to be rapid time perception (<39sec). Anxiety and depression scores were recorded as high in 12% of the patients. There was no significant correlation between TPD and anxiety (r=0.027, p=0.68) and depression scores (r= 0.017, p= 0.79). TPD was similar between the groups with high and normal anxiety scores (39 vs 39 sec, p= 0.90) and those with short perception patients were similar in both groups (51.7% vs 50.2%, p=0.51). TPD was shorter in those with high depression scores (34 vs 40s, p= 0.37). Those with rapid TDP were more common in these patients, but this did not reach statistical significance (58.6% vs 49.3%, p= 0.22). In the multivariate analysis. Female gender and low income were found to be risk factors for high anxiety scores.
Conclusions
The 1-minute time perception assessment could not be shown to be effective in predicting depression and anxiety scores. In our study, in which the group with high depression/anxiety scores was low, the small sample size may be the reason for the insignificant result. Testing the efficacy of 1 minute time perception in larger groups can provide important data to the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05